Finally, we aimed to test the Lateral MPC in three eye-related therapeutic SSOs that failed their respective clinical trials for Stargardt disease (QRX-1011,34 targeting ABCA4 c.5461-10T>C mutation), Leber congenital amaurosis type 10 (QR-110,35 for CEP290 c.2991 + 1655A>G mutation), and Usher syndrome (QR-421a,36 directed against USH2A exon 13). This evidence concerns the gene USH2A and Stargardt disease.